ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Researchers found better detection, treatment and decreased smoking have been immensely helpful in reducing deaths due to ...
According to the American Cancer Society, more than 2 million new cancer cases are estimated to have been diagnosed in the ...
ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the ...
Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...
Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...
Health and Me on MSN
Anktiva approved in Saudi Arabia as world’s first lung cancer therapy — all you need to know
Saudi Arabia approves Anktiva, an IL-15 immunotherapy, for bladder and lung cancer, marking its first regulatory clearance ...
A new cancer therapy wakes up immune cells inside tumors and turns them against cancer.
Some tumours are cancerous, but not all cancers can form tumours. How are cancers different from the abnormal pumps you ...
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback